Each study has a usefulness score out of 100 (rubric version 4.0). Tap a score to see what makes it up.
Highest usefulness score first. Studies without a score come last.
-
Neurodegeneration in fetal development of Down syndrome (DS) patients is proposed to result in apparent neuropathological abnormalities and to contribute to the phenotypic characteristics of mental retardation and premature development of Alzheimer disease.
Why it matters
This is an early laboratory study using mouse embryonic stem cells carrying a human chromosome 21, not a study in people. It identifies proteins that differ during early neuron development, which may help explain developmental abnormalities but does not test any treatment, cure, or prevention.
-
Recently, a frequent prion protein gene (PRNP) polymorphism consisting of a methionine (M) for valine (V) substitution at codon 129 has been associated with cognitive impairment in elderly individuals.
Why it matters
Among 122 relatively young people with Down syndrome, those carrying at least one valine allele of the PRNP codon 129 polymorphism showed a faster decline in intellectual ability. This describes a genetic influence on cognitive decline and does not test any treatment, cure, or prevention.
-
The t-complex polypeptide 1 is a selective molecular chaperone in tubulin biogenesis, by that nascent tubulin subunits are bound to t-complex polypeptide 1 and released in assembly competent forms.
Why it matters
This study found that the ratio of a molecular chaperone to its substrate is decreased in several brain regions of people with Alzheimer disease, but increased in some regions of people with Down syndrome. It suggests different mechanisms of protein aggregation, but it does not test any treatment or cure.
-
Neurofibrillary tangles (NFTs) form in a number of neurodegenerative disorders.
Why it matters
This tissue study found that most extracellular neurofibrillary tangles stained with antibodies to the 40 carboxy-terminal of beta-amyloid in Alzheimer disease, Down syndrome and Guam parkinsonism-dementia complex. The authors note the results may indicate a direct interaction between beta-amyloid and tangles, but secondary deposition or crossreactivity cannot be ruled out.
-
Polyamines may play an important role in brain development, mature brain function and also in neurodegenerative conditions.
Why it matters
Levels of the polyamines spermidine and spermine were markedly decreased in the frontal cortex of people who had died with Alzheimer's disease or Down syndrome compared with normal controls. The authors say this supports the idea that polyamine levels are altered in dementing illnesses, but the study does not show whether this change causes dementia or can be treated.
-
Genetic and other defects leading to brain changes in Down syndrome, Alzheimer disease, amyotrophic lateral sclerosis, Huntington disease, Gaucher disease, hypertension and other disorders are rapidly being identified.
Why it matters
This paper discusses the possibility that getting drugs, genes or proteins into the brain could help treat Alzheimer's disease and other conditions, since many promising treatments cannot reach the brain. It does not report any new treatment, trial or result in patients.
-
An anti-tau monoclonal antibody tau-2 was demonstrated to react with the cells which characteristically appeared in the subcortical nuclei of certain neurodegenerative disorders.
Why it matters
This study describes tau-2 positive microglia-like cells that appeared in subcortical nuclei, especially the putamen, in some cases of Alzheimer type dementia and diffuse Lewy body disease but not in Parkinson's disease, Pick's disease, or controls without neurological disorder. It is a descriptive pathological finding and reports no treatment, cure, or prevention for Alzheimer's disease.
-
A major component of amyloid deposits found in Alzheimer disease and Down syndrome is the beta/A4 peptide, which is derived from the Alzheimer amyloid protein precursor (APP).
Why it matters
Mice carrying the entire human amyloid precursor protein gene expressed the human protein in their brains. This is an early animal study supporting use of such mice to study amyloidosis, not a treatment or cure.
-
The association cortex of Down's syndrome (DS) predictably and prematurely undergoes neurofibrillary degeneration of Alzheimer type.
Why it matters
In Down's syndrome cortex, GFAP expression was lower than in controls except in one case with extensive neurofibrillary degeneration, and no Alzheimer-type mRNA changes appeared before neurofibrillary degeneration. This provides clues about the sequence of early changes in Down's syndrome and Alzheimer disease but does not test any treatment.
-
Transcriptional regulation of the gene encoding the amyloid precursor protein (APP) may play an important role in the formation of the amyloid depositions observed in Alzheimer disease and Down syndrome patients.
Why it matters
In Hela and PC12 cells, the study identified two blocks of regulatory sequences in the APP gene promoter, one acting as a positive regulator and one as a negative regulator. This is laboratory work on how the APP gene is controlled, not a treatment or prevention finding.
-
It was suggested that increased Cu-Zn superoxide dismutase (SOD-1) might be involved in the various biological abnormalities found in Down's syndrome (DS) such as premature aging and Alzheimer-type neurological lesions.
Why it matters
In transgenic mice with an extra copy of the human SOD-1 gene, increased SOD-1 activity in the brain did not cause the tau protein changes seen in neurofibrillary degeneration. This animal study suggests SOD-1 overexpression alone may not explain the tau pathology of Down syndrome and Alzheimer's disease, but it does not test a treatment.
-
Two cases of germ cell tumors (GCTs) of the basal ganglia are presented and 40 previously reported cases are reviewed.
Why it matters
This review describes germ cell tumors of the basal ganglia and thalamus, which can cause symptoms such as mental deterioration including dementia. These tumors are a different condition from Alzheimer's disease, and the study does not address treating, curing, or preventing Alzheimer's disease.
-
TDP-43 proteinopathies encompass frontotemporal lobar degeneration with TDP-43 pathology (FTLD-TDP), amyotrophic lateral sclerosis (ALS-TDP), and limbic predominant age related TDP-43 encephalopathy neuropathological change (LATE-NC).
Why it matters
This autopsy study compared a phosphorylation-independent antibody with a phospho-specific antibody for detecting TDP-43 pathology across frontotemporal lobar degeneration, ALS and LATE-NC, including in Alzheimer's disease neuropathologic change. The findings suggest the new antibody may be a complementary tool for subtype refinement and biomarker development, but this is laboratory and autopsy work, not a treatment study.
-
= 7.1 nM) and remarkable selectivity over other proteinopathies.
Why it matters
This tracer was tested in rodents and non-human primates, so it is still early-stage and not yet a proven tool in people. If it works in humans, it could help diagnose TDP-43-related diseases earlier and help evaluate therapies.
-
Furthermore, we showed that phosphorylated tau accumulates within the endo-lysosomal system of the CHCHD10 V57E -expressing flies and mammalian cells.
Why it matters
In fruit fly and cell culture models, the frontotemporal dementia-associated CHCHD10 V57E mutation worsened tau-related degeneration and caused phosphorylated tau to build up in the endo-lysosomal system. These are laboratory models only, so it is too early to say whether this mechanism can be targeted to treat people.
-
Loss-of-function progranulin ( GRN ) mutations cause frontotemporal dementia with TDP-43 pathology (FTD-TDP).
Why it matters
In mice with progranulin insufficiency crossed with human TDP-43 transgenic mice, progranulin insufficiency did not induce TDP-43 aggregation but worsened FTD-related phenotypes and altered RNA splicing. These results highlight dysfunction of mPFC neurons and dysregulated inflammation as potential drivers of disease progression in FTD-GRN, but the work is in mice.
-
The analyses supported stage-dependent remodeling of astrocyte-associated transcriptional and metabolic programs during disease progression.
Why it matters
This transcriptome-informed metabolic modeling study found stage-specific metabolic reprogramming in astrocytes during progression from mild cognitive impairment to Alzheimer's disease and highlighted astrocyte-centered pathways as potential targets for future research. It is a modeling study and does not test any treatment, cure, or prevention.
-
P. gingivalis-induced periodontitis dampened hippocampal Bmal1 rhythms, lowered p-AKT, activated glia, and elevated Aβ and interleukin 1β (IL-1β).
Why it matters
In this work, P. gingivalis oral infection suppressed PI3K/AKT signaling, disrupted glial circadian clocks and increased neuroinflammation and Alzheimer-like pathology in the hippocampus, while rescuing PI3K/AKT or clock function mitigated these effects. The authors suggest this pathway may be a target, but the findings are experimental and do not establish a treatment or prevention for people.
-
Tauopathies are neurodegenerative diseases characterized by pathological tau accumulation, leading to motor and neuropsychiatric symptoms.
Why it matters
An engineered single-domain antibody cleared tau through the autophagy-lysosomal pathway in neurons from patients with frontotemporal dementia and in JNPL3 tauopathy mice, and improved motor function in the mice. This is cell and animal work, so it does not yet show a treatment for people.
-
The cytoplasmic accumulation of TDP-43 aggregates remains a persistent pathological hallmark of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and limbic-predominant age-related TDP-43 encephalopathy (LATE).
Why it matters
This review discusses strategies to restore autophagic flux in TDP-43 proteinopathy, noting that classical autophagic activators like rapamycin cannot address downstream flux bottlenecks, and discusses newer approaches including TFEB activators, PROTACs and antisense oligonucleotides. It proposes that multi-targeting strategies and better biomarkers are needed, but reports no tested treatment, cure or prevention.
-
Pathological TAR DNA-binding protein-43 (TDP-43) is a defining feature of several neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Alzheimer's disease (AD).
Why it matters
This study found that cytoplasmic TDP-43 mis-localization induced microglial necroptosis through RIPK3, and that pharmacological inhibition of RIPK3 with GSK872 attenuated these effects in vitro and in a murine model. These findings identify necroptosis as a promising therapeutic target, but the work is in cells and mice, not humans.
-
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are devastating neurodegenerative diseases that, despite the availability of symptomatic and modestly beneficial treatments, still lack therapies capable of halting disease progression.
Why it matters
This is a conceptual review that organizes factors into a proposed cascade linking TDP-43 misfolding, phase separation, and clearance failure. It suggests that future treatments may need to go beyond simple clearance and target multiple steps in this cascade, but no treatment was tested.
-
Tau, mainly expressed in neurons and less expressed in glial cells (astrocytes and oligodendrocytes) and peripheral tissues, is involved in the assembly and stabilization of microtubules, and other biological processes such as axonal transport, metal ion transport, etc. Dysfunction of tau, caused by mutations, hyperphosphorylation, aggregation, or reduced expression, is closely associated with tauopathies (e.g., Alzheimer disease) and psychiatric disorders.
Why it matters
This review notes that tau-targeted therapies have shown limited efficacy in diseases despite reaching clinical trials. It summarizes tau biology and biomarker development while pointing to critical gaps in understanding tau's role and the translatability of treatments.
-
Dysregulation of the TAR DNA-binding protein 43 (TDP-43), including intraneuronal cytoplasmic mislocalisation and aggregation is a feature of multiple neurodegenerative diseases including amyotrophic lateral sclerosis (ALS), frontotemporal lobar dementia (FTLD), limbic-predominant age-related TDP-43 encephalopathy (LATE) and alzheimer’s disease (AD).
Why it matters
Zebrafish engineered to produce human TDP-43 in motor neurons developed motor problems, motor neuron loss and muscle wasting, and the ALS drug edaravone but not riluzole improved motor deficits in some of these models. This is early animal work that may inform drug testing, but it does not yet show any treatment for people.
-
There was a significant interaction between OSA and diagnosis for within- and between-DMN FC (p-values<0.05).
Why it matters
In older adults with Down syndrome, brain-network connectivity depended on both obstructive sleep apnea and cognitive status: among those with sleep apnea, people who were still cognitively stable had higher default mode network connectivity than those with cognitive impairment. No such difference appeared in people without sleep apnea. The authors suggest a distinct brain signature in Down syndrome with sleep apnea, with connectivity elevated before Alzheimer-related cognitive impairment and reduced after symptoms start.
From across this topic
10 of the 4,748 studies in this topic, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 10. The same 10 appear here every time.
- Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain
- A distinct familial presenile dementia with a novel missense mutation in the tau gene
- Development of [18F]ACI-19626 as a first-in-class brain PET tracer for imaging TDP-43 pathology
- mTOR in Down syndrome: Role in Aß and tau neuropathology and transition to Alzheimer disease-like dementia
- Loss of TREM2 Confers Resilience to Synaptic and Cognitive Impairment in Aged Mice
- White matter hyperintensities precede other biomarkers in GRN frontotemporal dementia
- Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid
- TBK1 Suppresses RIPK1-Driven Apoptosis and Inflammation during Development and in Aging
- Alpha-synuclein in Parkinson's disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
- Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease